Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin

Int J Androl. 1987 Feb;10(1):311-7. doi: 10.1111/j.1365-2605.1987.tb00198.x.

Abstract

This is a preliminary analysis of the AIO-Testicular Tumour Study Group trial in patients with disseminated bulky testicular cancer. Treatment plan: cisplatin 35 mg/m2 days 1-5, VP-16 120 mg/m2 days 1-5 (two daily divided doses), bleomycin 15 mg/m2 days 1, 8, 15. Of 98 patients at present evaluable 63% had complete remission or have no evidence of disease (CR/NED), 30% had partial remission (PR) and 7% had no change or progressive disease (NC/P). Relapse-free survival is 93% for the CR/NED group after a median follow up of 2.2 years: the overall survival for the entire patient population is 70%. Toxicity included predominantly granulocytopenic fever and infection with septicaemia, thrombocytopenia, nausea, vomiting, neurotoxicity and lung toxicity, with 7% fatal toxicity. A prospective randomized trial is warranted to evaluate the apparent superior activity of ultra high dose cisplatin in combination with VP-16 and bleomycin.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / toxicity
  • Bleomycin / administration & dosage
  • Bone Marrow / drug effects
  • Cisplatin / administration & dosage
  • Drug Evaluation
  • Follow-Up Studies
  • Humans
  • Leukopenia / chemically induced
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / pathology
  • Thrombocytopenia / chemically induced
  • Vinblastine / administration & dosage

Substances

  • Bleomycin
  • Vinblastine
  • Cisplatin

Supplementary concepts

  • PVB protocol